Novo Nordisk Shares Drop After Key Trial Failure
Shares of Novo Nordisk (NYSE:NVO) fell by nearly 9.4% after the company announced that its experimental heart drug, ziltivekimab, failed to reduce major adverse cardiovascular events in a key Phase 3 trial called 'Zeus.' While the drug successfully lowered inflammation markers like IL-6 and C-reactive protein, it did not lower patients' risk of heart attacks or strokes. Additionally, more participants experienced serious infections compared to those receiving a placebo. The failure is expected to impact Novo Nordisk's long-term revenue potential but will not affect its 2026 adjusted operating profit outlook. Two other trials for ziltivekimab—Hermes and Artemis—are still ongoing in different patient populations, raising concerns that similar results may emerge there as well. Despite the setback, Novo Nordisk remains a dominant player in GLP-1 obesity treatments with strong sales of Wegovy driving recent growth. The company's stock has faced volatility this year due to other setbacks, but its position in a rapidly growing market could still offer long-term opportunities.
Topics: biotech stocks cardiovascular disease drug development